• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Synaptogenix Inc.

    7/7/21 1:43:59 PM ET
    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNPX alert in real time by email
    SC 13G 1 ea143861-13galpha_synaptogen.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. ___)

     

    SYNAPTOGENIX, INC.

     

    (Name of Issuer)

     

    COMMON STOCK, $0.0001 PAR VALUE

     

    (Title of Class of Securities)

     

    234652419

     

    (CUSIP Number)

     

    July 7, 2021

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    (Continued on following page(s)

     

    Page 1 of 5 Pages

     

     

     

     

     

     

    CUSIP No. 234652419   13G   Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
       
      Alpha Capital Anstalt
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
      (a) ☐
      (b) ☐
    3.   SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Liechtenstein

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5. SOLE VOTING POWER, – 331,282 Common Stock (1)
       
    6. SHARED VOTING POWER - None
       
    7. SOLE DISPOSITIVE POWER – 331,282 Common Stock (1)
       
    8. SHARED DISPOSITIVE POWER – None
       

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -  
         
      331,282 Common Stock (1)  
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
         
      CERTAIN SHARES ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
         
      5.49%  
    12. TYPE OF REPORTING PERSON  
         
      CO  

     

    (1)Based on 6,038,798 shares outstanding as of July 1, 2021 as reported in the Form 424B3 filed with the Securities and Exchange Commission on July 7, 2021.

     

     

     

     

    CUSIP No. 234652419   13G   Page 3 of 5 Pages

     

    ITEM 1 (a) NAME OF ISSUER: Synaptogenix, Inc.

     

    ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    1185 Avenue of the Americas, 3rd Floor, New York, NY 10036

     

    ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein

     

    ITEM 2 (c) CITIZENSHIP: Liechtenstein

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $0.0001 par value

     

    ITEM 2 (e) CUSIP NUMBER: 234652419

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4 OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 331,282 Common Stock (1)

     

    (b) PERCENT OF CLASS: 5.49%

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    331,282 Common Stock (1)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    331,282 Common Stock (1)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

     

    CUSIP No. 234652419   13G   Page 4 of 5 Pages

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    CUSIP No. 234652419   13G   Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      July 7, 2021
      (Date)
       
      /s/ Konrad Ackermann
      (Signature)
       
      Konrad Ackermann, Director
      (Name/Title)

     

     

     

    Get the next $SNPX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

      New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK, July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2025. The new name and trading symbol coincides with the Company's previously announced digital asset treasury strategy focused exclusively on acquiring and staking TAO cryptocurrency. Executive Chairman Joshua Silverman commented, "With our team's deep knowledge of the TAO ecosystem and relationships in

      7/1/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

      New trading symbol "TAOX" effective Tuesday, July 1, 2025, New name represents Company's strategic focus on the synergies between cryptocurrency and AI NEW YORK, June 26, 2025 /PRNewswire/ -- TAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), today announced that it will begin trading on Nasdaq under the new ticker symbol "TAOX" on Tuesday, July 1, 2025, in accordance with its rebranding to the new name TAO Synergies Inc., effective today. The Company's new corporate identity aligns with its significant  strategic focus on the leading AI token TAO as the cornerstone of its digital asset treasury strategy. TAO is the leading AI token by market capitalization and

      6/26/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:07:09 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:45 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:21 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Synaptogenix Inc.

      PRE 14A - TAO Synergies Inc. (0001571934) (Filer)

      6/27/25 4:02:10 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TAO Synergies Inc. (0001571934) (Filer)

      6/27/25 4:00:50 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Synaptogenix, Inc. (0001571934) (Filer)

      6/24/25 4:37:19 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

      Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo

      4/9/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Financials

    Live finance-specific insights

    See more
    • Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

      Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD).  The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,

      7/26/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Corporate Update Conference Call

      NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo

      7/21/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

      NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.  Analyses of treatment benefit, based on mean differences and as a function of successive dosing in

      7/26/21 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/6/24 10:16:19 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/8/23 6:05:21 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      1/18/23 4:28:57 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care